Harvard evolutionary biologist Daniel Lieberman joins Chris Williamson to discuss what an evolutionary perspective can and cannot add to modern debates about dieting, and why he says many dietary movements become tribal. Lieberman argues that large-scale evidence tends to favour plant-heavy diets over meat-heavy ones, while cautioning that nutrition research is difficult to interpret because diets substitute for one another and lifestyle factors confound observational studies.
He cites specific studies and mechanisms to explain why Mediterranean-style eating has strong support, including the Spanish PREDIMED trial, which he says was stopped early due to marked benefits. He is sceptical of marketing claims around “optimal” diets and criticises Blue Zones longevity branding, citing work he attributes to Oxford demographer Saul Newman that questions age-record reliability.
On longevity interventions, Lieberman says calorie restriction extends lifespan in some lab species but claims the evidence does not yet translate cleanly to primates or humans, describing a macaque replication he says found no longevity advantage. He also addresses intermittent fasting as “metabolic switching” between growth and repair pathways.
Lieberman calls processed and ultra-processed foods the dominant driver of obesity, discusses how food engineering (fat-sugar-salt combinations and texture) promotes overeating, and notes that calorie labels can misrepresent absorbed energy. On treatment, he says GLP-1 drugs can be transformative but raises concerns about muscle loss, high discontinuation, and weight regain, arguing prevention still depends on fixing the food environment and improving nutrition education.
Daniel Lieberman says Blue Zones diet marketing overstates evidence for living to 100, citing research he attributes to Oxford demographer Saul Newman. He argues many reported centenarians lack birth certificates and that self-reported ages make some longevity claims unreliable.
Read this moment →Discussing calorie restriction as a longevity strategy, Lieberman says a headline-making Wisconsin macaque study was confounded because the control group were effectively fed an unhealthy, obesity-promoting diet. He claims a later NIH replication using comparable diets, with a 30% calorie reduction arm, found no difference in longevity or health outcomes.
Read this moment →Lieberman says GLP-1 drugs are “game changers” for weight loss but warns they may also cause substantial lean-mass loss, raising later frailty risk, particularly as patients age. He says he and colleagues published on the issue in JAMA, and advises strength training for people using the medications to help preserve muscle.
Read this moment →Lieberman outlines a biochemical pathway by which omega-6 fats could, in theory, contribute to inflammatory compounds, but says human feeding studies don’t show that increasing omega-6 intake increases inflammation. He adds that epidemiological studies he cites associate higher omega-6 intake with better health outcomes, including lower risks of heart disease and some cancers.
Read this moment →Daniel Lieberman says the last study he saw found about 60% of GLP-1 users quit after a year or two. He argues that appetite often returns after stopping, making weight maintenance difficult and pushing some people towards long-term use.
Read this moment →Daniel Lieberman says Spain’s PREDIMED trial was stopped early because researchers judged it unethical to withhold a Mediterranean-style diet from the control group. He argues the trial adds to a stronger evidence base for Mediterranean-style eating than other named diets.
Read this moment →